2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 388-390
Before and After: Optimizing Conditioning and Maintenance in HCT
Treatment Considerations, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Radiation Therapy, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, Research, AML, Clinical Research, Health Outcomes Research, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

135 A prospective Phase 2 study of venetoclax plus decitabine–intensified conditioning followed by decitabine maintenance for TP53-mutated AML/MDS undergoing allo-HCT

Xiangjun Zeng, MD, Yeqian Zhao2, Chuanhe Jiang3, Jian Yu4, Yi Yu5, Congxiao Zhang6, Yishan Ye, MD7, Huarui Fu8, Fei Gao9, Qingxiao Chen, MD10, Pingnan Xiao11, He Huang, PhD12, Yang Cao, MD13, Li Yu14, Xiaoxia Hu, MD15, Jimin Shi16, Yanmin Zhao, MD17
1 Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou 310006, China., Hangzhou, China
2 Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou 310006, China., Hangzhou, China
3 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
4 Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou 310006, China., Hangzhou, China
5 Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou 310006, China., Hangzhou, China
6 Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou 310006, China., Hangzhou, China
7 Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou 310006, China., Hangzhou, China
8 Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou 310006, China., Hangzhou, China
9 Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou 310006, China., Hangzhou, China
10 Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou 310006, China., Hangzhou, China
11 Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou 310006, China., Hangzhou, China
12 Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou 310006, China., Hangzhou, China
13 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
14 Department of Hematology, The Second Affiliated Hospital of Nanchang University, Nanchang, China
15 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
16 Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou 310006, China., Hangzhou, China
17 Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou 310006, China., Hangzhou, China

Background: Despite the potentially curative role of allogeneic hematopoietic cell transplantation (HCT), patients with TP53-mutated acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) remain at high risk of relapse and death, highlighting the urgent need for novel peri-transplant strategies to eradicate TP53-mutated clones and prevent relapse. Herein, we evaluated an integrated peri-transplant strategy combining venetoclax plus decitabine-intensified conditioning with post-HCT decitabine maintenance for TP53-mutated AML and MDS.

 

Methods: This prospective, multicenter, single-arm phase 2 trial enrolled patients aged 12–70 years with TP53-mutated AML or MDS who were scheduled to undergo first allogeneic HCT (NCT05528354). Venetoclax 400 mg/day for 7 days and decitabine 20 mg/m²/day for 5 days were added to protocol-defined myeloablative or reduced-toxicity conditioning. Patients in remission with donor chimerism >95% and adequate hematologic recovery could receive decitabine 5 mg/m²/day on days 1–5 every 6–8 weeks for up to 6 cycles. The primary endpoint was 1-year relapse-free survival (RFS). Secondary endpoints included overall survival (OS), cumulative incidence of relapse (CIR), non-relapse mortality (NRM), engraftment, graft-versus-host disease (GVHD), safety, and longitudinal TP53 measurable residual disease (MRD) assessed by digital PCR.

 

Results: Between August 2022 and May 2025, 58 patients received protocol-specified conditioning and underwent HCT. Median age was 55 years (range, 21-69); 36 patients (62%) had MDS and 22 (38%) had AML. Complex or monosomal karyotype was present in 32 patients (55%), TP53 multi-hit disease in 31 (53%), and 28 (48%) were in CR/CRi/CRL before HCT. 38 patients (66%) received myeloablative conditioning, and 52 (90%) underwent haploidentical HCT.

After a median follow-up of 25.6 months, the study met its primary endpoint: the 1- and 2-year RFS rates were 66.8% (95% CI, 55.6%–80.2%) and 57.2% (95% CI, 45.1%–72.6%), respectively. The corresponding OS rates were 74.4% (95% CI, 63.6%-87.0%) and 65.1% (95% CI, 53.0%-79.9%). The CIR at 1 and 2 years were 19.2% (95% CI, 10.2%-30.3%) and 23.9% (95% CI, 13.3%-36.1%), respectively, while the corresponding NRM estimates were 14.1% (95% CI, 6.5%-24.5%) and 18.9% (95% CI, 9.5%-30.8%).

 

The median neutrophil and platelet recovery both occurred at 13 days. The cumulative incidences of grade II-IV acute GVHD were 12.1% by day 100 and 13.8% by day 180, while those of moderate-to-severe chronic GVHD were 20.0% and 22.1% at 1 and 2 years, respectively. Forty-three patients (74%) initiated decitabine maintenance at a median of 102 days after HCT and received a median of 3 cycles.

 

Among patients with detectable TP53 variants before HCT, median log10 VAF reductions were 2.8 at day 30 and 3.2 at day 60. Of 30 maintenance recipients harboring serial MRD assessments, 4 of 7 with detectable MRD before maintenance achieved clearance, while 18 of 23 MRD-negative patients remained negative. Persistent or recurrent MRD occurred in 8 patients, 6 of whom subsequently experienced hematologic relapse. Exploratory analysis showed TP53 multi-hit status was associated with inferior RFS (HR, 2.7; 95% CI, 1.1–6.6, p = 0.026) and OS (HR, 3.2; 95% CI, 1.2–8.9; p = 0.024), whereas no significant associations were observed for diagnosis, sex, age, or donor type.

 

All planned conditioning regimens were completed without interruption. The most common grade ≥3 treatment-emergent adverse events were nausea and vomiting (26%), diarrhea (16%), febrile neutropenia (12%), pulmonary infection (9%), and sepsis (5%); one patient died from sepsis. No tumor lysis syndrome or sinusoidal obstruction syndrome occurred. During maintenance, grade 3 leukopenia and thrombocytopenia occurred in 10% of patients each, and grade 3 neutropenia and anemia in 7% each.

 

Conclusions: Venetoclax plus decitabine-intensified conditioning followed by decitabine maintenance was feasible and associated with encouraging disease control in this high-risk population. The marked early reduction in TP53 molecular burden supports biologic activity of the peri-transplant platform, whereas the independent contribution of maintenance requires evaluation in a controlled study.

Yanmin Zhao, MD: No relevant conflicts of interest to declare.